"The voice for cancer physicians and their patients in Massachusetts."

  • Home
  • Resources
  • FDA Approvals
  • FDA Approves lenalidomide (Revlimid) as Maintenance Therapy for MM Patients After Autologous Hematopoietic Stem Cell Transplantation (auto-HSCT)

FDA Approves lenalidomide (Revlimid) as Maintenance Therapy for MM Patients After Autologous Hematopoietic Stem Cell Transplantation (auto-HSCT)

23 Mar 2017 7:29 AM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration (FDA) has approved lenalidomide (Revlimid) as maintenance therapy for multiple myeloma (MM) patients after autologous hematopietic stem cell transplantation (auto-HSCT). Read full press release. 

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software